Biotech Startups

Delphian Tx is a clinical-stage biopharmaceutical company developing cannabinoid-based drugs (CBD:THC combinations) targeting the endocannabinoid system to treat migraine and other complex pain and CNS disorders. The company has a Phase 1 clinical trial ongoing and issued USPTO patents.

1 investor

Delphinium is a boutique clinical research organization (CRO) based in Groningen, Netherlands, that conducts early-phase clinical trials with a focus on healthy volunteers across therapeutic areas including cardiology, neurology, and metabolic diseases. The company operates its own clinical research unit with 12 beds and in-house pharmacy, offering services in pharmacokinetics/pharmacodynamics, first-in-human, and bioequivalence studies.

1 investor

Delta Life Science develops rapid, sensitive, and low-cost biosensor technology and instruments for analyzing biomarker concentrations in life sciences research and diagnostics. The company, which originated from TNO research, serves academic institutions and the pharmaceutical industry with tools for biomolecular interaction analysis.

1 investor

Deltamune manufactures registered and autogenous vaccines for poultry health, protecting birds against diseases including infectious coryza, egg drop syndrome, and salmonella infections. Operating from a GMP-certified facility in South Africa since 2008, the company serves poultry producers and veterinarians with custom vaccine solutions and commercial vaccine products.

1 investor

Delve develops molecular next-generation sequencing (mNGS) tests that diagnose infections in cerebrospinal fluid and other clinical samples, enabling rapid pathogen identification for patients with difficult-to-diagnose infections.

1 investor

Demeetra is a genome engineering company that develops precision gene-editing platforms — including Cas-CLOVER, Harbor-IN and Super piggyBac transposases and CleanCut CHO host cell lines — along with integrated cell line development and GMP manufacturing services. It serves biopharmaceutical developers through flexible licensing and service models for cell line development, biomanufacturing, and discovery programs.

1 investor

DENCODA develops DNA-based diagnostic assays that detect enzyme activity to identify diseases including osteoarthritis, kinase-related cancers, and protease-linked conditions. The company serves clinicians, researchers, and patients seeking early disease detection and diagnosis.

1 investor

DenovAI Biotech uses artificial intelligence and computational molecular biophysics to design proteins de novo, building platforms for rapid antibody discovery and bespoke high-affinity binders. The company targets therapeutic and diagnostic applications, including antibodies, peptide biologics, and diagnostic reporters for drug discovery.

1 investor

De novo Biotherapeutics is a biotherapeutics company developing an mRNA platform to make high-end therapies more affordable. Its lead work focuses on mRNA-based engagers targeting relapsed or refractory cancers, with plans for phase 1 clinical studies.

1 investor

Dermaliq Therapeutics is a specialty pharmaceutical company developing topical dermatology therapies and medical skin care products based on its proprietary hyliQ drug-delivery platform, with a lead pipeline focused on hair loss conditions such as androgenetic alopecia and alopecia areata. Its candidates target delivery of active molecules into hair follicles and skin for patients with pattern hair loss, immune-mediated hair loss, and wound healing.

1 investor

Desentum is a clinical-stage biopharmaceutical company developing allergen immunotherapy products that reprogram immune responses to allergens toward tolerance. The company targets both respiratory and food allergies, with its lead asset currently in phase II clinical trials.

1 investor

DesiCorp develops advanced packaging and stabilization solutions for biopharmaceutical and therapeutic products, extending shelf-life without refrigeration to improve access in rural, remote, and emergency care settings. The company uses specialized materials and two-chambered packaging designs to preserve sensitive compounds during transport and storage in austere environments.

1 investor

1 investor

Detective Biosciences is developing a blood-based cancer detection test that analyzes patients' DNA epigenetic profiles. The company operates in the cancer diagnostics and biotech space.

1 investor

Detraxi is a privately held company developing emerging technology, seeking development funding and licensing partnerships. The page provides limited detail about the specific product or industry.

1 investor

DeuterOncology is a clinical-stage biotech developing DO-2, a deuterated, brain-penetrant MET kinase and RAS pathway inhibitor for cancer patients, currently in a phase 1 clinical study. The molecule was in-licensed from OCTIMET Oncology and originally from Janssen Pharmaceutica.

1 investor

Dexcom develops continuous glucose monitoring (CGM) systems and glucose biosensors, including the Dexcom G7 and the over-the-counter Stelo biosensor, that send real-time glucose readings to a phone or receiver. Its products serve people managing diabetes as well as consumers tracking glucose for general health, diet, and exercise.

1 investor

Dextera Biosciences develops dexabodies, a therapeutic modality built from D-amino acids that resists degradation by natural enzymes while retaining antibody-like specificity in a compact format, and can be conjugated to payloads such as steroids or toxins for targeted delivery. The company applies this synthetic D-protein platform to debilitating diseases with significant unmet medical need.

1 investor

Dharmacon Reagents provides synthetic oligonucleotides, gene modulation, and gene editing solutions for functional genomics research, enabling researchers to study genetic networks and advance therapeutic discovery. The company offers a comprehensive range of tools for DNA, RNA, and protein-level research, including RNAi, CRISPR gene editing, and screening libraries for academic and commercial researchers.

1 investor

ModalityDx develops quantitative point-of-care diagnostic tests using molecular biomarkers and data science to detect and assess treatment response for diseases including diabetes, maternal health conditions, and autoimmune disorders. The company also supports pharmaceutical firms in drug development and therapeutic efficacy assessment.

1 investor

Diaceutics provides intelligence and engagement solutions that help biopharma companies commercialize precision medicine and diagnostic-driven therapies, using data from US labs to identify eligible patients and engage the physicians and labs involved in testing and treatment decisions. It serves pharmaceutical and biopharma teams across pre-launch, launch and in-market stages, primarily in the US diagnostics and precision medicine market.

1 investor

Diagnóstica Longwood is a distributor of in vitro diagnostics technologies, supplying NGS-based assays, kits and reagents for molecular diagnostics in areas such as oncology, hereditary and rare diseases, and microbiology. Founded in 1992, it serves clinical and research laboratories with technical support and its own inventory in Spain.

1 investor

Diamante develops plant-based compounds for therapeutic and diagnostic systems targeting autoimmune diseases. The company applies molecular farming techniques to produce biopharmaceuticals and aims to advance treatments from research to clinical applications.

1 investor

Diamidex develops microbiological analysis solutions for water safety, including equipment, software, and reagents designed to detect and count targeted microorganisms with improved speed and accuracy for laboratory use.

1 investor